Medicaid Provider SpendingClaims paid 2018–2024 · HHS public file
Home › CA › Walnut Creek › NPI 1740215219
Hospital

John Muir Health

John Muir Health was paid $32.37M by Medicaid between Jan 2018 and Dec 2024, across 260 billing codes. Its largest line is J3490, Unclassified drugs — 41% of everything it billed.

33Billing provider infoJOHN MUIR HEALTH
WALNUT CREEK, CA 94598
33aNPI1740215219assigned 07/12/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$32.37M
24GClaims549,527
24DCodes billed260
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers

Next to other General Acute Care Hospital providers in California

Rank by total paid#88 of 410
Median peer was paid$6.90M
This provider vs. median4.7×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

$0$500K$1.0M2018201920202021202220232024
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
YearClaimsPaid
201867,136$5.22M
201963,817$3.15M
202051,284$2.55M
202171,778$3.51M
202286,442$5.24M
202399,075$5.72M
2024incomplete109,995$6.98M
Box 24 · Service lines

What it billed for

CodeServiceShareClaimsBene. recordsPaid
J3490 Unclassified drugs 41% 71,856 30,515 $13.34M
0450 Emergency room services 7.1% 59,037 53,326 $2.30M
0121 6.2% 245 235 $2.01M
82803 4.2% 1,141 1,110 $1.38M
0202U Oncology (prostate), multianalyte, gene expression profiling 3.3% 3,668 3,626 $1.07M
74177 Computed tomography, abdomen and pelvis; with contrast material 2.2% 3,824 3,753 $710K
96374 Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance 1.9% 10,650 9,875 $600K
0272 1.7% 5,549 5,365 $565K
G0480 Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed 1.3% 2,821 2,665 $426K
Q0162 Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen 1.2% 5,473 5,282 $376K
0123 1.1% 57 51 $359K
78815 Positron emission tomography (PET) for limited area imaging 1.1% 268 267 $348K
248 more codes
0241U Neonatal screening for hereditary disorders, genomic sequence analysis panel 1.1% 2,710 $341K
93005 Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report <1% 15,855 $310K
70450 Computed tomography, head or brain; without contrast material <1% 3,849 $303K
80053 Comprehensive metabolic panel <1% 25,822 $273K
C9803 Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source <1% 6,181 $264K
J7030 Infusion, normal saline solution , 1000 cc <1% 11,413 $221K
87635 Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe <1% 4,485 $209K
85025 Blood count; complete (CBC), automated, and automated differential WBC count <1% 30,462 $209K
96361 Intravenous infusion, hydration; each additional hour <1% 8,693 $207K
96376 <1% 2,697 $199K
96375 Therapeutic injection; each additional sequential IV push <1% 7,008 $196K
0250 <1% 2,008 $192K
96360 Intravenous infusion, hydration; initial, 31 minutes to 1 hour <1% 3,221 $188K
74176 Computed tomography, abdomen and pelvis; without contrast material <1% 1,576 $164K
99199 Unlisted special service, procedure or report <1% 3,186 $162K
72125 Computed tomography, cervical spine; without contrast material <1% 1,417 $151K
93976 <1% 871 $151K
76705 Ultrasound, abdominal, real time with image documentation; limited <1% 3,274 $148K
71045 Radiologic examination, chest; single view <1% 10,110 $148K
96372 Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular <1% 6,632 $147K
0171 Inj, epinephrine (belcher) <1% 108 $145K
71046 Radiologic examination, chest; 2 views <1% 6,662 $140K
80307 Drug test(s), presumptive, any number of drug classes; immunoassay <1% 1,543 $134K
71260 Computed tomography, thorax, diagnostic; with contrast material <1% 1,080 $130K
76856 Ultrasound, pelvic (nonobstetric), real time with image documentation; complete <1% 2,428 $125K
99283 Emergency room visit (moderate) <1% 1,662 $125K
77067 Screening mammography, bilateral, including computer-aided detection <1% 1,397 $124K
97110 Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion <1% 9,095 $121K
87502 Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets <1% 1,549 $113K
70498 <1% 647 $109K
76830 Ultrasound, transvaginal <1% 1,906 $100K
97140 Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) <1% 4,331 $96K
99281 Emergency department visit for the evaluation and management, self-limited or minor <1% 1,202 $94K
99284 Emergency room visit (serious) <1% 2,171 $91K
U0003 Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r <1% 1,233 $91K
97530 Therapeutic activities, direct patient contact, each 15 minutes <1% 4,475 $90K
93306 Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete <1% 363 $90K
84484 <1% 10,345 $89K
93971 <1% 1,123 $87K
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml <1% 6,482 $84K
96365 Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour <1% 1,111 $81K
71275 Computed tomographic angiography, chest, with contrast material <1% 419 $77K
87651 Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe <1% 2,153 $74K
70496 <1% 332 $67K
80048 Basic metabolic panel (calcium, ionized) <1% 5,740 $67K
99070 <1% 1,914 $64K
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries <1% 277 $64K
76801 <1% 977 $63K
83690 <1% 9,636 $60K
76770 <1% 1,026 $59K
76700 Ultrasound, abdominal, real time with image documentation; complete <1% 941 $57K
0720 <1% 2,228 $53K
59025 Fetal non-stress test <1% 2,012 $52K
0122 <1% 15 $50K
84703 <1% 7,964 $49K
80320 <1% 423 $48K
81001 <1% 16,095 $48K
76642 <1% 952 $43K
87086 Culture, bacterial; quantitative colony count, urine <1% 6,180 $42K
99233 Hospital visit by a doctor, follow-up day (complex) <1% 976 $41K
97161 <1% 831 $39K
77386 <1% 108 $38K
76817 Ultrasound, pregnant uterus, real time with image documentation, transvaginal <1% 610 $38K
74018 <1% 2,058 $35K
J2405 Injection, ondansetron hydrochloride, per 1 mg <1% 6,678 $35K
77066 Tomosynthesis, mammo <1% 384 $34K
94664 <1% 2,351 $33K
83880 <1% 1,309 $33K
97139 <1% 2,016 $33K
84443 Thyroid stimulating hormone (TSH) <1% 2,176 $32K
Z7502 <1% 1,369 $31K
73564 <1% 1,393 $31K
77063 Screening digital breast tomosynthesis, bilateral <1% 1,353 $30K
J2270 Injection, morphine sulfate, up to 10 mg <1% 3,525 $30K
87040 <1% 3,402 $29K
84702 <1% 2,307 $29K
J1885 Injection, ketorolac tromethamine, per 15 mg <1% 5,042 $29K
0510 <1% 1,214 $28K
99291 Critical care, evaluation and management of the critically ill patient, first 30-74 minutes <1% 252 $28K
73630 <1% 1,309 $26K
T1999 Miscellaneous therapeutic items and supplies, retail purchases, not otherwise classified; identify product in "remarks" <1% 1,917 $25K
70553 Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences <1% 126 $24K
83605 <1% 3,086 $23K
J1170 Injection, hydromorphone, up to 4 mg <1% 2,373 $21K
80306 <1% 393 $20K
73030 <1% 976 $20K
77301 <1% 26 $19K
76536 <1% 382 $19K
73610 <1% 923 $18K
77065 Tomosynthesis, mammo <1% 257 $18K
82553 <1% 349 $16K
87077 <1% 2,367 $15K
71250 <1% 160 $15K
87491 Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe <1% 689 $15K
J0696 Injection, ceftriaxone sodium, per 250 mg <1% 1,996 $15K
72100 <1% 643 $14K
0002A <1% 359 $14K
93010 Electrocardiogram, routine ECG with at least 12 leads; interpretation and report only <1% 1,041 $13K
87186 <1% 1,886 $13K
0001A <1% 323 $13K
99232 Hospital visit by a doctor, follow-up day <1% 339 $12K
87591 Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe <1% 687 $11K
85379 <1% 1,223 $11K
77049 <1% 32 $10K
77336 <1% 269 $10K
77300 <1% 106 $10K
J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme <1% 1,626 $10K
77338 <1% 55 $10K
85730 <1% 1,982 $10K
J7050 Infusion, normal saline solution, 250 cc <1% 1,830 $9K
85610 <1% 2,885 $9K
83735 <1% 1,558 $9K
A9585 Injection, gadobutrol, 0.1 ml <1% 360 $9K
73130 <1% 356 $8K
72110 <1% 206 $8K
86901 <1% 3,231 $7K
97162 <1% 156 $7K
87661 Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe <1% 230 $7K
J1200 Injection, diphenhydramine hcl, up to 50 mg <1% 1,302 $7K
86900 <1% 2,921 $7K
86850 <1% 2,448 $7K
97014 <1% 759 $7K
80047 <1% 1,099 $7K
85027 <1% 1,729 $7K
J2704 Injection, propofol, 10 mg <1% 345 $6K
94729 <1% 123 $6K
0360 <1% 117 $6K
87633 Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets <1% 16 $6K
J0780 Injection, prochlorperazine, up to 10 mg <1% 426 $5K
G0299 Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes <1% 33 $5K
70486 <1% 52 $5K
J2060 Injection, lorazepam, 2 mg <1% 990 $5K
77334 <1% 49 $5K
J3010 Injection, fentanyl citrate, 0.1 mg <1% 988 $4K
73110 <1% 207 $4K
87070 <1% 450 $4K
87507 <1% 12 $4K
73502 <1% 135 $4K
J7611 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg <1% 345 $4K
J7120 Ringers lactate infusion, up to 1000 cc <1% 523 $4K
82550 <1% 712 $4K
86140 <1% 797 $4K
J1100 Injection, dexamethasone sodium phosphate, 1 mg <1% 598 $3K
0420 <1% 298 $3K
0636 <1% 304 $3K
76377 <1% 296 $3K
77062 <1% 338 $3K
Z7610 <1% 423 $3K
84145 <1% 153 $3K
J8540 Dexamethasone, oral, 0.25 mg <1% 508 $3K
90715 <1% 99 $3K
72040 <1% 126 $2K
J7512 Prednisone, immediate release or delayed release, oral, 1 mg <1% 794 $2K
97112 Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination <1% 170 $2K
82150 <1% 952 $2K
73140 <1% 144 $2K
0710 <1% 237 $2K
0762 <1% 492 $2K
83036 Hemoglobin; glycosylated (A1C) <1% 239 $2K
97165 <1% 29 $2K
97166 <1% 25 $2K
76870 <1% 40 $2K
J1815 Injection, insulin, per 5 units <1% 106 $2K
J2765 Injection, metoclopramide hcl, up to 10 mg <1% 251 $2K
94726 <1% 39 $1K
85652 <1% 655 $1K
J1756 Injection, iron sucrose, 1 mg <1% 22 $1K
J1650 Injection, enoxaparin sodium, 10 mg <1% 149 $1K
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit) <1% 229 $1K
73080 <1% 57 $1K
73590 <1% 86 $1K
77061 <1% 135 $1K
J1171 Injection, hydromorphone, 0.1 mg <1% 49 $971.21
84439 <1% 126 $949.82
85049 <1% 319 $934.37
85014 <1% 366 $925.90
36430 <1% 3,222 $907.36
Q0163 Diphenhydramine hydrochloride, 50 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at time of chemotherapy treatment not to exceed a 48 hour dosage regimen <1% 223 $850.42
0370 <1% 32 $826.88
G0108 Diabetes outpatient self-management training services, individual, per 30 minutes <1% 13 $823.32
J2001 Injection, lidocaine hcl for intravenous infusion, 10 mg <1% 122 $823.00
94060 <1% 26 $749.19
77077 <1% 25 $690.87
87420 <1% 166 $599.27
85018 <1% 330 $596.05
72082 <1% 14 $591.22
0270 <1% 278 $548.76
88305 Level IV - Surgical pathology, gross and microscopic examination <1% 12 $537.31
87581 <1% 16 $511.97
87486 <1% 16 $511.97
87798 Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism <1% 17 $488.00
84450 <1% 106 $463.59
85048 <1% 247 $447.43
84075 <1% 106 $434.40
82247 <1% 106 $430.19
82040 <1% 107 $427.05
97039 <1% 26 $415.92
72050 <1% 13 $413.49
0300 <1% 392 $408.08
82565 <1% 225 $387.39
J3480 Injection, potassium chloride, per 2 meq <1% 36 $378.85
0301 <1% 464 $372.65
90471 Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine <1% 62 $364.53
80051 <1% 178 $349.97
72070 <1% 13 $327.34
J2250 Injection, midazolam hydrochloride, per 1 mg <1% 65 $314.31
96366 Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour <1% 14 $313.12
84155 <1% 106 $312.33
73560 <1% 31 $306.79
73620 <1% 13 $236.34
J0131 Injection, acetaminophen, not otherwise specified,10 mg <1% 14 $231.20
81003 <1% 112 $222.63
J0690 Injection, cefazolin sodium, 500 mg <1% 33 $199.96
82947 <1% 182 $196.96
S0265 Genetic counseling, under physician supervision, each 15 minutes <1% 13 $195.00
84520 <1% 192 $192.40
72170 <1% 14 $169.44
J2930 Injection, methylprednisolone sodium succinate, up to 125 mg <1% 14 $164.24
87210 <1% 41 $153.83
73070 <1% 12 $117.60
82570 <1% 24 $110.86
84550 <1% 29 $105.07
J1644 Injection, heparin sodium, per 1000 units <1% 16 $104.70
82330 <1% 12 $103.68
97035 <1% 18 $102.01
J7613 Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg <1% 78 $92.83
82248 <1% 16 $70.28
83615 <1% 14 $64.44
84156 <1% 13 $42.38
87205 <1% 14 $38.35
84295 <1% 12 $30.00
84132 <1% 12 $29.72
G1004 Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program <1% 150 $0.02
0258 0% 98 $0.00
0410 0% 99 $0.00
0306 0% 276 $0.00
0307 0% 158 $0.00
0305 0% 404 $0.00
0324 0% 157 $0.00
0271 0% 104 $0.00
0310 0% 25 $0.00
80329 0% 28 $0.00
0730 0% 166 $0.00
0470 0% 93 $0.00
0302 0% 135 $0.00
0402 0% 77 $0.00
0320 0% 84 $0.00
0430 0% 12 $0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialKNIGHT, CALVIN (PRESIDENT AND CHIEF EXECUTIVE OFFIC)